New HIV vaccine combo passes early safety check in 34 volunteers
NCT ID NCT05182125
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested two experimental HIV vaccines in 34 healthy, HIV-negative adults. The goal was to see if the vaccines were safe and whether they triggered an immune response. The vaccines use a harmless chimpanzee virus to deliver HIV proteins, followed by a booster shot. This is a step toward developing a vaccine to prevent HIV infection, not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aurum Institute Klerksdorp CRS
Klerksdorp, South Africa
-
CAPRISA eThekwini CRS
Durban, South Africa
-
Emavundleni CRS
Cape Town, South Africa
-
Isipingo CRS
Isipingo, South Africa
-
Setshaba Research Centre CRS
Soshanguve, South Africa
-
Soweto HVTN CRS
Johannesburg, South Africa
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peer-led prevention: can gancheros help stop HIV, hepatitis c, and overdose in NYC?
- Small cash rewards may keep HIV-positive mothers in treatment — a trial puts the idea to the test
- Long-acting HIV shot studied in patients with severe kidney problems
- Can two hours of mindfulness ease chronic pain in HIV patients?
- Can a clinic-and-social-media campaign boost HIV prevention among black women?
- Choice of Long-Acting HIV prevention could transform care for young people in rural south africa